Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. N-diethylmethylammoniummethyl-p-(2-(n-octyloxy)benzoyl)aminobenzoate Bromide
2. Octylonium
3. Octylonium Bromide
4. Octylonium Iodide
5. Spasmomen
1. 26095-59-0
2. Octylonium Bromide
3. Otilonium (bromide)
4. Sp63
5. Doralin
6. Spasmoctyl 40
7. 21hn3n72pv
8. Spasmomen
9. Sp-63
10. Otilonium Bromide (inn)
11. Diethyl(2-hydroxyethyl)methylammonium Bromide P-(o-(octyloxy)benzamido)-benzoate
12. Diethyl-methyl-[2-[4-[(2-octoxybenzoyl)amino]benzoyl]oxyethyl]azanium;bromide
13. Dsstox_cid_26357
14. Dsstox_rid_81559
15. Dsstox_gsid_46357
16. Otilonium Bromide [inn]
17. Otilonii Bromidum
18. Ottilonio Bromuro
19. N,n-diethyl-n-methyl-2-(4-(2-(octyloxy)benzamido)benzoyloxy)ethanaminium Bromide
20. Ottilonio Bromuro [italian]
21. Bromure D'otilonium
22. Bromuro De Otilonio
23. Otilonium Bromide [inn:ban]
24. Cas-26095-59-0
25. Otilonii Bromidum [inn-latin]
26. Bromure D'otilonium [inn-french]
27. Bromuro De Otilonio [inn-spanish]
28. Ncgc00163507-01
29. Einecs 247-457-4
30. Unii-21hn3n72pv
31. Octylonium Bromide;sp63
32. Diethyl(2-hydroxyethyl)methylammonium Bromide P-(o-(octyloxy)benzamido)benzoate
33. Ethanaminium, N,n-diethyl-n-methyl-2-((4-((2-(octyloxy)benzoyl)amino)benzoyl)oxy)-, Bromide
34. Mls006011208
35. Schembl109554
36. Otilonium Bromide [mi]
37. Chembl2103773
38. Dtxsid0046357
39. Hy-b0499a
40. Otilonium Bromide [mart.]
41. Hms3651l16
42. Hms3885i05
43. Otilonium Bromide [who-dd]
44. Bcp09737
45. Tox21_112059
46. Mfcd00211142
47. Otilonium Bromide, >=98% (hplc)
48. S3047
49. Akos015833077
50. Tox21_112059_1
51. Ccg-270064
52. Ks-1278
53. Ammonium, Diethyl(2-hydroxyethyl)methyl-, Bromide, P-(o-(octyloxy)benzamido)benzoate
54. N,n-diethyl-n-methyl-2-((4-(2-(octyloxy)benzamido)benzoyl)oxy)ethan-1-aminium Bromide
55. N,n-diethyl-n-methyl-2-((4-(2-(octyloxy)benzamido)benzoyl)oxy)ethanaminium Bromide
56. Ncgc00163507-03
57. Ethanaminium, N,n-diethyl-n-methyl-2-[[4-[[2-(octyloxy)benzoyl]amino]benzoyl]oxy]-, Bromide (1:1)
58. Smr004702974
59. Ft-0630523
60. Sw219209-1
61. D07083
62. Q920900
63. J-016250
64. J-523842
Molecular Weight | 563.6 g/mol |
---|---|
Molecular Formula | C29H43BrN2O4 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 17 |
Exact Mass | 562.24062 g/mol |
Monoisotopic Mass | 562.24062 g/mol |
Topological Polar Surface Area | 64.6 Ų |
Heavy Atom Count | 36 |
Formal Charge | 0 |
Complexity | 600 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
Calcium Channel Blockers
A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)
Gastrointestinal Agents
Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)
Parasympatholytics
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)
A03AB06
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
A - Alimentary tract and metabolism
A03 - Drugs for functional gastrointestinal disorders
A03A - Drugs for functional gastrointestinal disorders
A03AB - Synthetic anticholinergics, quaternary ammonium compounds
A03AB06 - Otilonium bromide
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?